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g.2013.0Abstract Background: While abnormal folate/homocysteine metabolism has been implicated as
an etiology for the development of both CHD and DS, recent studies and meta-analyses did not
consider MTHFR C677T genotype as a maternal risk factor for either of these conditions alone.
Aim of work: To investigate if methylenetetrahydrofolate reductase (MTHFR) C677T genotype
is a maternal risk factor for the development of congenital heart disease (CHD) only in children
with Down syndrome (DS).
Subjects and methods: Molecular analysis of MTHFR C677T and serum folic acid was done for
sixty-one consecutive mothers of children with CHD in the form of septal defects (26 with DS and
35 without DS) and another 61 mothers of apparently healthy children (without DS or CHD).
Results: The frequency of CT genotype was signiﬁcantly higher in mothers of children with AV
canal (whether in DS or non-DS) when compared to ASD and in mothers of DS with AV canal
when compared to controls. The frequency of TT genotype was higher in mothers of DS with
ASD than controls but statistically insigniﬁcant. In non-DS mothers, the distribution of the geno-
types did not differ in relation to the type of CHD. The mean folic acid level did not differ between
different study groups.
Conclusions: MTHFR 677CT genotype could be implicated as a maternal risk factor for septal
defects especially in children with DS. Carriers of this genotype may have more risk of development
of AV canal in their children. A major limitations of this study was the small sample size and so
further studies on a larger sample of patients and their mothers in addition to measurement ofedical Genetics Center, 27A
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40 G.M. Elsayed et al.homocysteine level in this population is needed to investigate this theory and to clarify the actual
role of MTHFR polymorphism and the risk of development of CHD in DS.
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Methylenetetrahydrofolate reductase (MTHFR) is one of the
most important enzymes in folate/homocysteine metabolism.
It is responsible for the conversion of 5,10-methylenetetrahy-
drofolate to 5-methyltetrahydrofolate and regulates the intra-
cellular ﬂow of folate through the conversion of
homocysteine to methionine for nucleotide synthesis. C677T
and A1298C polymorphisms in the MTHFR gene affect this
pathway by reducing enzyme activity and subsequently in-
crease total plasma homocysteine and decrease serum folate
levels [1,2]. In 1999, James et al. hypothesized that the
MTHFR 677CT polymorphism might be a risk factor for
maternal meiotic nondisjunction and Down syndrome (DS)
in young mothers [3]. Since then, several studies on MTHFR
polymorphism have been carried out on different populations
including Egyptians [4,5]. Results were controversial, while
James et al. [3], Scala et al. [6] and Rai et al. [7] reported a sig-
niﬁcant increased risk, Coppede et al. did not report a signiﬁ-
cant difference [8]. Actually, despite 10 years of active research,
the question is still unsolved. Overall, both in vitro and in vivo
studies indicate that an impaired folate/homocysteine metabo-
lism can result in chromosome 21 nondisjunction; however, the
birth of a DS child seems to be the result of the interplay of
several factors of genetic, epigenetic, environmental, and sto-
chastic origin, making it difﬁcult to discriminate the single con-
tribution of each of them [8].
MTHFR gene polymorphisms have been also implicated in
the etiology of congenital heart defects (CHD) [1,9]. Previous
studies showed that the overall risk of heart defects can be re-
duced by multivitamin supplements (including folic acid) espe-
cially in some septal defects (ventricular septal defect (VSD))
and some conotruncal anomalies (teratology of Fallot and
transposition of great arteries) [10,11].
Recently, the relationship between MTHFR genotype and
the development of CHD in DS has been investigated and data
were controversial in different populations [12,13]. In fact, sev-
eral genes encoding for the reduced folate carrier (SCL19A1 or
RFC1) and the cystathionine beta synthetase are located on
chromosome 21 for which trisomies increase folate demand
in the developing DS fetus. DS cases with atrioventricular sep-
tal defects (AVSD) shared signiﬁcantly more alleles across
SCL19A1 than expected suggesting an association between
variation of this gene and AVSD [14].
The aim of this study was to assess the relationship between
the maternal MTHFR C677T genotype and the development
of certain types of CHD as septal defects in their children with
DS in our Egyptian population.2. Subjects and methods
The study included 61 consecutive Egyptian mothers of chil-
dren with septal defects (with or without DS) from June
2009 to June 2010 who did not receive folic acid supplementa-
tion in the periconceptional period (Folic acid food fortiﬁca-tion is not a current policy yet in Egypt). All patients and
mothers were recruited from the Ain Shams University Hospi-
tal which is a tertiary governmental hospital in which most of
the patients are low economy class with poor diet. The hospital
is the second largest hospital in Cairo and receives patients
from all governorates all over Egypt. Although it is a homog-
enous population, it is known that the Egyptians have a mixed
genetic background with an ethnic heterogeneity with most of
the population of Mediterranean or Arabic origin. The study
group was in Hardy–Weinberg equilibrium. The population
was not chosen from any isolates or members from the same
family.
Exclusion criteria included women who started to use folate
supplements after known that they were pregnant, mothers of
children with other congenital anomalies, a recognized genetic
syndrome or chromosome anomalies other than DS and moth-
ers receiving antiepileptic drugs (valproic acid, phenytoin, car-
bamazepine) since all can alter folic acid metabolism and
increase the risk of congenital anomalies.
The CHD included only septal defects: atrial septal defects
(ASD), venricular septal defect (VSD), ASD+VSD, and atrio-
ventricular (AV) canal. Diagnosis of septal defects was made
clinically and conﬁrmed by echocardiography done by an ex-
pert pediatric cardiologist. They were subdivided into 2
groups:
- Group 1 (mothers of children with DS): mothers of karyo-
typically ascertained non-disjunction DS children with sep-
tal defects from the Genetics Clinic, Children’s Hospital,
Ain Shams University (n= 26)
- Group 2 (mothers of non-DS children): mothers of children
with septal defects from the Cardiology Clinic, Children’s
Hospital, Ain Shams University (n= 35).
Sixty-one women serving as controls were mothers of
apparently healthy children (without DS or CHD) who did
not receive folic acid supplementation in the periconceptional
period. The study was approved by the ethical committee of
the institute and informed consent was obtained from all
mothers. The work was carried out in accordance with the
code of ethics of the World Medical Association (declaration
of Helsinki) (http://www.wma.net/en/30publications/10poli-
cies/b3/index.html).3. Methods
3.1. Molecular method
Genomic DNA was extracted using QIAamp DNA extraction
kit (Cat „ 51104). Polymerase chain reaction (PCR) was per-
formed according to the method described by Frosst et al.
[1]: Two primers were used for analysis of the C-T mutation.
MTHFR F: 50-TGA AGG AGA AGG TGT CTG CGG
GA-30 and MTHFR R: 50-AGG ACG GTG CGG TGA
GAG TG-30:
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volume containing 5 ll of 10· buffer (100 mM; Tris–HCl,
500 mM KCL, (NH4)2SO4, 15 mM; MgCL2, pH = 8.7),
0.2 mM each dNTPs, 0.4 lM primers, and one unit of Taq
DNA polymerase enzyme (Qiagen, cat#20123). The PCR con-
sisted of initial denaturation at 94 C for 150 s followed by 35
cycles at 94 C for 30 s, 57 C for 60 s, 72 C for 120 s and a
ﬁnal elongation step at 72 C for 3 min. The PCR product of
198 bp was analyzed using 100 bp ladder on 1.5% agarose
gel electrophoresis. Twenty ll of PCR product was mixed with
10 units of Hinf1 (Promega, Madison) enzyme and incubated
at 37 C overnight. The substitution creates a Hinf1 recogni-
tion sequence that is digest of 198 bp into 175-bp and 23-bp.
To ensure quality control, the presence of C > T polymor-
phism was performed with blinding to case/control status,
non-template control and positive/ampliﬁcation genotype con-
trol was included within each experimental PCR run. Ten per-
cent sample cases and controls were genotyped twice and
reproducibility was 100%.
3.2. Serum folic acid level
Whole blood was collected after overnight fast for all subjects
in a vacutainer tube without anticoagulant. Samples were left
undisturbed at 4–8 C until complete clot formation was ob-
served. Clotted samples were then centrifuged at 2000g for
10 min. Serum was collected and aliquottes were stored at
70 C until analyzed. The level of serum folic acid was quan-
tiﬁed using competitive chemiluminescent immumoassay
(IMMULITE Analyzer, Cat#LKFO1, SIMENS), [15].
3.3. Statistical methods
Data were expressed as mean ± SD (range) or as number (%)
of cases. Comparison of proportions and means between both
groups was made by using the chi-square test and independent
t-test, respectively. The Fisher’s exact test was used when
applicable. ANOVA (Analysis of variance) was used to test
the difference about mean values of folic acid among groups,
multiple comparisons between pairs of groups were performedTable 1 Comparison of frequencies of MTHFR C677T genotypes
MTHFR C677T ge
CCa
Study groups
Mothers of DS, N (%) 11 (42.3)
Mothers of non-DS, N (%) 19 (38.8)
Controls, N (%) 30 (49.2)
DS versus controls
OR (95%CI)
P
Non-DS versus controls
OR (95%CI)
P
DS versus non-DS
OR (95%CI)
P
a Reference category, Chi-square test, Fisher’s Exact Test.using Bonferroni test (Post hoc range test). Results were pre-
sented as mean and SD. Analysis was performed by using
the Statistical Package for the Social Sciences (SPSS, ver-
sion15). The level P< 0.05 was considered the cut-off value
for signiﬁcance.
4. Results
The mean age of DS mothers was 30.5 ± 6.39 years (range:
20–40), non-DS mothers 29.4 ± 5.94 years (range: 22–42)
and controls was 28.9 ± 6.69 years (range: 18–45). Septal de-
fects included: ASD in 14 children (7 DS and 7 non-DS),
VSD in 19 (3 DS and 16 non-DS), ASD+VSD in 14 (7 DS
and 7 non-DS), AV canal in 10 (5 DS and 5 non-DS) and 4 pa-
tients with PFO (2 DS and 2 non-DS).
Although the frequencies of MTHFR C677T genotypes did
not show statistically signiﬁcant difference between different
study groups, none of the mothers of patients with non-DS
had the TT genotype, (Table 1).
The mean folic acid level did not show signiﬁcant difference
between mothers of DS (13.87 ± 4.71 ng/ml) and the controls
(13.75 ± 5.32 ng/ml) or mothers of non-DS (12.35 ± 4.06 ng/
ml). It did not also show a signiﬁcant difference in relation to
MTHFR C677T genotypes, (Table 2).
In comparing all mothers to controls, mothers of patients
with ASD did not show a signiﬁcance difference regarding
the CT or the TT genotypes compared to controls (P= 0.10
(OR, 0.25, 95%CI: 0.05–1.25) and P> 0.99, (OR, 0.86,
95%CI: 0.15–4.82), respectively). The same was found in
mothers of patients with VSD , ASD+VSD, and AV canal
who showed non-signiﬁcant difference of CT genotype com-
pared to controls (P= 0.60, 0.77 (OR, 1.39, 95%CI: 0.49–
3.96), (OR, 1.25, 95%CI: 0.39–4.06) and P= 0.08 (OR, 5,
95%CI: 0.97–25.8), respectively). Interestingly, it was noted
that the 80% of patients with AV canal has the CT genotype
(whether in DS or non-DS). It was signiﬁcant when compared
only to mothers of ASD (P= 0.008, OR 20, 95% CI: 2.29–
175.04). This means that those mothers with CT genotype have
more risk to have a baby with AV canal than to have a baby
with ASD, (Table 3).between different study groups.
notype
TT CT
3 (11.5) 12 (46.2)
0 (0) 16 (40)
7 (11.5) 24 (39.3)
1.17 (0.26–5.34) 1.36 (0.51–3.63)
>0.99 0.62
0.81 (0.69–0.95) 1.05 (0.45–2.47)
0.08 >0.99
0.79 (0.60–1.03) 0.77 (0.27–2.22)
0.07 0.79
Table 4 MTHFR C677T genotype in relation to type of septal defect in mothers of children with DS.
Type of Septal defects, N (%) Controls, N (%)
ASD (7) VSD (3) ASD+VSD (7) AV canal (5)
MTHFR C677T genotype CC 3 (42.9) 2 (66.7) 4 (57.1) 0 (0) 30 (49.2)
TT 2 (28.6) 0 (0) 0 (0) 0 (0) 7 (11.5)
CT 2 (28.6) 1 (33.3) 3 (42.9) 5 (100) 24 (39.3)
Chi-square test with Bonferroni correction (level of signiﬁcance 6 0.01).
Table 2 Comparison between MTHFR C677T genotypes in relation to the level of folic acid in different studied groups.
MTHFR C677T genotype
Folic acid (ng/ml) CC TT CT F P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Mothers of DS 13.08 ± 4.64 13.20 ± 3.81 14.88 ± 5.31 0.34 0.72
Mothers of non-DS 11.33 ± 3.14 14.23 ± 5.11 1.58 0.13
Controls 11.36 ± 3.68 20.23 ± 7.55 14.98 ± 4.91 6.95 0.003
The differences in mean level in groups were tested using one-way analysis of variance. Multiple comparisons were performed using Bonferroni
test.
Table 3 MTHFR C677T genotypes in relation to different septal defect types in all mothers in the study group.
All mothers, N (%) Controls, N (%)
ASD (14) VSD (19) ASD+VSD (14) AV canal (10)
MTHFR C677T genotype CCa 10 (71.4) 9 (47.4) 7 (50) 2 (20) 30 (49.2)
TT 2 (14.3) 0 (0) 0 (0) 0 (0) 7 (11.5)
CT 2 (14.3) 10 (52.6) 7 (50) 8 (80) 24 (39.3)
a Reference category. Chi-square test with Bonferroni correction (level of signiﬁcance 6 0.01).
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of CT genotype was also signiﬁcantly higher in mothers of DS
with AV canal (P= 0.01, OR: 1.21, 95%CI: 1.02–1.43). On
the other hand, the frequency of the CT genotype did not show
a signiﬁcant difference in mothers of DS with ASD, VSD, and
ASD+VSD compared to controls (P> 0.99 (OR, 0.83,
95%CI: 0.13–5.40), P> 0.99 (OR, 0.63, 95%CI: 0.05–7.31)
and (OR, 0.94, 95%CI: 0.19–4.60), respectively).
This statistically insigniﬁcant relation was also noted in the
frequency of TT genotype but an interesting high OR value
was noted in mothers of DS and ASD (2.86) so we may say
that DS mothers with this genotype had more risk to have chil-
dren with ASD, although this relation is weak as CI is only 0.4
(P= 0.28, OR: 2.86, 95%CI: 0.4–20.5), (Table 4). On the
other hand, in mothers of non-DS, the frequency of MTHFR
677CT genotype did not differ in relation to the type of septal
defects (data not shown).
5. Discussion
The precise role of folate during cardiacmorphogenesis remains
unclear. Biochemically, folate is a one-carbon donor, as such in-
volved in many important cellular reactions, including the syn-
thesis of nucleotides and methyl transfer reactions important
for methylation of DNA, proteins, and lipids [16]. In 1999, Jill
James and colleagues reported that a particular variant (poly-
morphism) ofMTHFRmight be a maternal risk factor for hav-
ing a child with DS and that a signiﬁcant increase in plasmahomocysteine levels exists in mothers of these children. This
genotype is known to decrease the activity ofMTHFR enzyme
[3]. Since then, several studies have been carried out on DS chil-
dren from different populations including Egypt which sup-
ported an independent contribution of the MTHFR C677T
allele to DS risk [4]. Whether these patients had CHD or not
was not reported. Precise data about the frequency and the type
ofCHDwere not reported aswell in other studies (as researchers
included all types of CHD collectively) [3,6,7,17].
Our study included only mothers of children with septal de-
fects (DS and non-DS). It showed that mothers of DS had
insigniﬁcant higher frequencies of both MTHFR 677 CT and
TT genotypes compared to mothers of non-DS and higher fre-
quencies of CT genotype compared to controls. Brandalize
et al. reported an inﬂuence of MTHFR polymorphism on the
occurrence of CHD in children with DS although they did
not specify the type of CHD that affected 37.6% of their pa-
tients [12]. However, Bozovic et al. could not support these
data in Croatian DS population [13].
Because children with DS in this study had septal defects, it
could be suggested that MTHFR genotype could be an impor-
tant risk factor in this particular type of children (DS + septal
defect). The implicating factor could be more than simply the
folic acid level as mean serum level was comparable in all
groups including the controls. It is known that serum/plasma
folate level is a very useful indicator to diagnose deﬁcient or
excessive status and to estimate the needed additional folate in-
take to reach speciﬁc cutoff points associated with reducing
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level was suggested as a cut off value required to reduce neural
tube defect occurrence above the plateau rate for ‘‘normal’’
populations [18]. Only one DS mother had this low level
(6.3 ng/ml) that had MTHFR CC genotype. Differences in
the level of susceptibility of individuals to potentially adverse
effects of environmental inﬂuences due to MTHFR genotype
may be an important contributor to the presence or absence
of this gene-disease association. Beside the chromosomal
anomaly, maternal risk factors may interact with susceptible
genotype resulting in more pronounced malformations in some
individuals [19].
Several genes participating in folate/homocysteine metabo-
lism are located on chromosome 21 and therefore over-ex-
pressed in DS. This includes SCL19A1 gene which was
found to be associated with AVSD [14].
We also noted that 80% of mothers of all patients with AV
canal had the CT genotype but it was statistically signiﬁcant
only on DS mothers (all mothers had the CT genotype). Reut-
ter et al. reported a mother and her child who had DS and AV
canal, both were homozygous to MTHFR 677TT genotype
[20]. These interesting ﬁndings should be further investigated
by a larger scale study on more children with DS and various
CHD especially that AV canal is a neural crest related defect,
but ASD is not related to neural crest [21,22] which contradicts
the previous belief that only neural crest related disease is af-
fected by folic acid metabolism [23].
Amajor limitation of this work was the lack of assessment of
fetalMTHFRC677T genotypes. It is recognized that the mater-
nal genetic effect can be confounded by the fetal genetic effect
and that models considering one should adjust for the other.
6. Conclusions
MTHFR 677CT genotype could be implicated a maternal risk
factor for septal defects especially in children with DS. Carriers
of this genotype may have more risk of development of AV ca-
nal in their children. A major limitations of this study was the
small sample size and so further studies on a larger sample of
patients and their mothers in addition to measurement of
homocysteine level in this population is needed to investigate
this theory and to clarify the actual role of MTHFR polymor-
phism and the risk of development of CHD in DS.
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